<DOC>
	<DOCNO>NCT01128881</DOCNO>
	<brief_summary>The primary objective study prospectively document exposure IMMUNINE monitor FIX inhibitor period approximately 20 50 exposure day receive prophylactic treatment 50 previously treat patient ( PTPs ) age 12-64 year approximately 20 pediatric PTPs 11 year age severe ( FIX level &lt; 1 % ) moderately severe ( FIX level &lt; = 2 % ) hemophilia B plan enter BAX326 study 250901 , provide eligibility criterion meet . In addition , study evaluate efficacy , safety , immunogenicity , thrombogenicity , health-related quality life ( HR QoL ) subject .</brief_summary>
	<brief_title>IMMUNINE Pre-Treatment Study</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Subject 64 year old time screen Subject and/or legal representative has/have provide sign informed consent Subject severe ( FIX level &lt; 1 % ) moderately severe ( FIX level &lt; = 2 % ) hemophilia B ( base one stage activate partial thromboplastin time ( aPTT ) assay ) , test screening central laboratory Subject previously treat plasmaderived recombinant FIX concentrate ( ) , cryoprecipitate fresh frozen plasma ( FFP ) approximately 100150 exposure day ( EDs ) &gt; = 6 year old , 2050 EDs &lt; 6 year old , plan enter BAX326 study 250901 . The number EDs derive subject 's treatment regimen his/her bleed pattern Subject willing receive prophylactic treatment duration study Subject immunocompetent evidence CD4 count &gt; = 200 cells/mm ( 3 ) Subject human immunodeficiency ( HIV ) negative HIV+ viral load &lt; 200 particles/μL ~ &lt; 400,000 copies/mL Female subject childbearing potential , present negative serum pregnancy test , agree employ adequate birth control measure duration study Subject willing able comply requirement protocol The subject detectable factor IX inhibitor screening , titer &gt; = 0.6 Bethesda Units ( BU ) determine Nijmegen modification Bethesda assay central laboratory The subject history factor IX inhibitor titer &gt; = 0.6 BU ( determine Nijmegen modification Bethesda assay assay employ respective local laboratory ) time prior screen The subject history allergic reaction , eg , anaphylaxis , follow exposure factor IX concentrate ( ) The subject know hypersensitivity hamster proteins The subject evidence thrombotic disease , fibrinolysis disseminate intravascular coagulation ( DIC ) The subject schedule elective surgery , unless surgery medically require within anticipated study period The subject abnormal renal function ( serum creatinine &gt; 1.5 time upper limit normal ) The subject severe chronic liver disease evidence , limited , follow : International Normalized Ratio ( INR ) exceed upper limit normal ( ULN ) , hypoalbuminemia , portal vein hypertension include presence otherwise unexplained splenomegaly history esophageal varices The subject active hepatic disease alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level &gt; = 5 time upper limit normal . During study , subject chronic hepatitis B C may fluctuations 5 time upper limit normal require discontinuation . The subject diagnose inherit acquire hemostatic defect hemophilia B The subject 's platelet count &lt; 100,000/mL The subject clinically significant medical , psychiatric , cognitive illness , recreational drug/alcohol use , opinion investigator , would affect subject 's safety compliance The subject currently receive , schedule receive course study , immunomodulating drug antiretroviral chemotherapy ( eg , αinterferon , corticosteroid agent dose equivalent hydrocortisone great 10 mg/day ) The subject unwilling consider participation BAX 326 ( rFIX ) pivotal study 250901 BAX 326 pediatric study The subject participate another investigational study within 30 day enrollment schedule participate another clinical study involve investigational product ( IP ) investigational device course study The subject member team conduct study dependent relationship one study team member . Dependent relationship include close relative ( ie , child , partner/spouse , sibling , parent ) well employee investigator site personnel conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>